Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide is the active ingredient in Wegovy, a once-weekly injection pen licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. It works by activating GLP-1 receptors in the brain and gut, reducing appetite and slowing how quickly food leaves the stomach. In the STEP 1 clinical trial, participants using the 2.4mg weekly dose lost an average of around 15% of their body weight over 68 weeks, published in the New England Journal of Medicine. Because it is a prescription-only medicine, a clinician must assess whether it is appropriate for you before any supply can take place. This page is here to help you understand how the pen works, who it is likely to suit, and what questions are worth asking before you decide.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The semaglutide injection pen is a pre-filled, pre-set device. Each pen contains four weekly doses; you inject once a week into the fatty tissue of your abdomen, thigh or upper arm, rotating the site each time. There is nothing to draw up, no separate needle to attach from scratch, and no dose calculation on your part. For people who have never injected before, that simplicity matters.
What semaglutide does inside the body is worth understanding, because it changes how you relate to food rather than simply suppressing willpower. GLP-1 receptors in the hypothalamus receive a stronger signal of satiety, which means the urge to eat (particularly between meals) tends to quiet down. Gastric emptying slows, so meals feel substantial for longer. Neither of these effects is dramatic on any single day; over weeks, the cumulative shift in eating patterns is where the clinical results come from.
One misconception worth setting aside gently: many people assume the pen is doing all the work, and that diet barely matters. The trial results, including those in the STEP 1 paper, were achieved alongside a reduced-calorie diet and increased physical activity. The injection makes those changes easier to sustain; it does not replace them. That framing is worth taking seriously before starting.
The semaglutide injection is the backbone of Wegovy treatment, and understanding the mechanism helps set realistic expectations for the months ahead.
Treatment does not begin at the full maintenance dose. The standard pathway starts at 0.25mg weekly, stepping up roughly every four weeks through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg. The MHRA also approved a higher 7.2mg dose in January 2026, initially as three 2.4mg pens weekly, with a dedicated single-dose 7.2mg pen approved in April 2026 for adults with a BMI of 30 or above.
The reason for starting low is straightforward: the side-effect profile is dominated by gastrointestinal symptoms, and the body adapts to the medicine more comfortably when the dose climbs gradually. Nausea, loose stools, reflux and fatigue are most common at the start of a new dose level and typically ease within one to two weeks. Rushing the schedule tends to make those effects worse and harder to sustain through.
Your prescriber sets the titration pace based on your individual response, it is not a rigid calendar so much as a clinical framework. If a step causes prolonged discomfort, staying at the current dose longer before progressing is a legitimate option, and one worth discussing rather than pushing through. The NHS patient information for semaglutide, published at nhs.uk/medicines/semaglutide, covers what to expect at each stage in plain language and is worth reading alongside anything your prescriber tells you.
For a closer look at how to use the pen correctly, practical guidance on using semaglutide for weight loss covers injection technique, site rotation and what to do if you miss a dose.
The UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not determine suitability; a prescriber looks at the full picture, including your medical history and current medicines.
Semaglutide is not recommended during pregnancy, while breastfeeding, or for people who are actively trying to conceive. It is not licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or a history of pancreatitis, need a careful prescriber conversation before starting.
If you take an oral contraceptive pill, safety considerations for the semaglutide injection are worth reviewing, NHS guidance notes that while the evidence for semaglutide reducing pill absorption is less definitive than for tirzepatide, discussing contraception with your prescriber before starting is sensible.
If you are curious how this medicine compares to tirzepatide, Wegovy pen options and the choices available gives a broader view of where each medicine sits. For a sense of what private treatment costs, our weight-loss treatment overview covers pricing context clearly.
Semaglutide for weight management is a prescription-only medicine. That means supply without a valid prescription from a registered clinician is illegal, and, given that counterfeit pens have been seized in significant numbers by the MHRA, the risk of buying from unverified sources is not theoretical. The MHRA has warned explicitly about fake weight-loss pens circulating online and via social media; you can report any suspect seller at the MHRA Yellow Card scheme.
Any legitimate online pharmacy dispensing Wegovy should be registered with the GPhC and should require a clinical assessment before issuing a prescription, and people searching for semaglutide weight loss injections near me will find that verifying a pharmacy on the GPhC register takes about thirty seconds and is the most direct way to check you are dealing with a regulated service.
At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day, a real clinician, not automated triage. Orders placed before noon on a working day are dispatched the same day once clinically approved, arriving by tracked DPD delivery the next working day, in plain packaging. If you are based in Scotland and want to explore your local options, our page on Wegovy injections in Glasgow explains what regulated treatment looks like in that area. If you are considering starting, the straightforward first step is to start your free consultation and let a prescriber assess your situation properly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.